 |
市場調査レポート
商品コード
1447872
悪性中皮腫の世界市場規模、シェア、成長分析、用途別、タイプ別 - 産業予測、2024年～2031年Global Malignant Mesothelioma Market Size, Share, Growth Analysis, By Application(Hospital Pharmacies, Retail Pharmacies), By Type(Oral, Parenteral) - Industry Forecast 2024-2031 |
||||||
| 悪性中皮腫の世界市場規模、シェア、成長分析、用途別、タイプ別 - 産業予測、2024年～2031年 |
|
出版日: 2024年02月26日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
悪性中皮腫の世界市場規模は2022年に1億5,393万米ドルと評価され、2023年の1億6,270万米ドルから2031年には2億5,351万米ドルに成長し、予測期間（2024年～2031年）のCAGRは5.7%で成長する見通しです。
中皮腫患者の擁護団体や支援ネットワークは、中皮腫というがんとの世界の闘いにおいて重要な柱となっています。中皮腫に対する認識を高め、早期発見を促進し、中皮腫と闘っている人々に重要な支援を提供する上で、これらの団体の努力は非常に重要です。これらの団体は、アドボカシー活動、教育イニシアティブ、アウトリーチプログラムを通じて不可欠な役割を果たし、患者のケアを大幅に向上させています。中皮腫に罹患した人々に支援とリソースを提供することで、困難な道を歩む患者が直面する負担を軽減する上で極めて重要な役割を果たしています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- セカンダリおよびプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
悪性中皮腫の世界市場：用途別
- 市場概要
- 病院薬局
- 小売薬局
- 腫瘍センター
- その他
悪性中皮腫の世界市場：タイプ別
- 市場概要
- 経口
- 非経口
悪性中皮腫の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- AstraZeneca
- Bristol-Myers Squibb
- Roche
- Merck
- Novartis
- Pfizer
- Sanofi
- Eli Lilly
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Mylan
- Fresenius Kabi
- Sun Pharmaceuticals
- Corden Pharma
- Concordia International
- Kyowa Hakko Kirin
- Polaris Pharmaceuticals
- MolMed
- Ono Pharmaceutical
- Nichi-Iko Pharmaceutical
Global Malignant Mesothelioma Market size was valued at USD 153.93 million in 2022 and is poised to grow from USD 162.70 million in 2023 to USD 253.51 million by 2031, growing at a CAGR of 5.7% in the forecast period (2024-2031).
Advocacy groups and support networks for mesothelioma patients serve as crucial pillars in the worldwide battle against this form of cancer. Their efforts are instrumental in raising awareness, promoting early detection, and furnishing vital support to individuals grappling with mesothelioma. These organizations fulfill an indispensable role through their advocacy, educational initiatives, and outreach programs, significantly enhancing patient care. By offering assistance and resources to those affected by the disease, they play a pivotal role in easing the burdens faced by patients on their difficult path.
Top-down and bottom-up approaches were used to estimate and validate the size of the Malignant Mesothelioma Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Malignant Mesothelioma Market Segmental Analysis
The global malignant mesothelioma market is segmented into three major segments i.e. by type, application, region. Based on type the market is segmented as, oral, parenteral. Based on application the market is segmented as, hospital pharmacies, retail pharmacies, oncology centers, other. Based on region the market is segmented as, North America, Europe, Asia-Pacific, MEA, and Latin America.
Drivers of the Malignant Mesothelioma Market
The surge in advancements in diagnostic methodologies plays a pivotal role in the detection of malignant mesothelioma cases. Significant enhancements in diagnostic techniques and tools have been witnessed over time, contributing to the early identification and diagnosis of this cancer. These improvements, coupled with heightened awareness among healthcare professionals and the public, have facilitated early detection and diagnosis, resulting in a higher reported incidence of cases at earlier stages.
Restraints in the Malignant Mesothelioma Market
A notable constraint in this context is the extended duration taken for diagnosis, which can impede timely intervention. Malignant mesothelioma is characterized by a prolonged latency period, often spanning several decades from initial asbestos exposure to symptom manifestation. This lengthy timeline poses a considerable challenge, delaying early diagnosis and intervention for individuals at risk.
Market Trends of the Malignant Mesothelioma Market
One of the key trends influencing the market is the aging population, which significantly contributes to the rising incidence of malignant mesothelioma. The cancer is more prevalent among older demographics, and with the global population aging, the likelihood of new cases is expected to increase. Moreover, the extended latency period for mesothelioma means that individuals exposed to asbestos earlier in life may develop the disease as they age.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Malignant Mesothelioma Market by Application
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Oncology Centers
- Others
Global Malignant Mesothelioma Market by Type
- Market Overview
- Oral
- Parenteral
Global Malignant Mesothelioma Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Corden Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Concordia International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kyowa Hakko Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Polaris Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MolMed
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ono Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nichi-Iko Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
